Business News

Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion

BRISBANE, Calif.–(BUSINESS WIRE)–Aug. 31, 2020– Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value …

Read More »

Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications

Pratteln, Switzerland, and Rockville, MD, USA, September 2, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has signed agreements with Idorsia (SIX: IDIA) and ReveraGen BioPharma Inc., making Santhera a direct license holder of vamorolone. Under the agreements, Santhera has obtained an exclusive license from ReveraGen, the originator of vamorolone, for …

Read More »

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program. JTX-1811 is a monoclonal antibody designed to …

Read More »

Boston Pharmaceuticals Licenses Non-Alcoholic Steatohepatitis Development Candidate from Novartis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Boston Pharmaceuticals today announced an agreement with Novartis through which Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH). NASH occurs in 12 percent of patients with nonalcoholic fatty liver disease (NAFLD) when the liver becomes inflamed …

Read More »

Leo Pharma and Elektrofi Enter Exclusive License Agreement to Develop Monoclonal Antibodies Using Elektrofi’s High-Concentration, Low-Volume Delivery Technology

BOSTON & BALLERUP, Denmark–(BUSINESS WIRE)–Elektrofi, Inc., a Boston-based biotechnology company focused on drug formulation and delivery innovations, and LEO Pharma A/S, a global leader in medical dermatology, today announced an exclusive license agreement to develop subcutaneously administered antibodies using Elektrofi’s high-concentration, low-volume delivery technology. Under the terms of the agreement, …

Read More »

LEO Pharma Sells Portfolio of Four Products to Cheplapharm

BALLERUP, Denmark–(BUSINESS WIRE)–Today, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million. The agreement represents a milestone in the roll-out of LEO Pharma’s 2030 strategy which increases the company’s focus on new innovative solutions for medical dermatology. The divested portfolio …

Read More »

Natera Partners with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

SAN CARLOS, Calif., Aug. 27, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali®), a CDK4/6 inhibitor, for the …

Read More »

Assembly Biosciences and Arbutus Biopharma Collaborate to Evaluate the Combination of ABI-H0731 with AB-729 in Patients with Chronic Hepatitis B Virus Infection

SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI-H0731 in combination …

Read More »

Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth. “Acquiring Acessa Health strengthens our leadership …

Read More »

ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio

SAN DIEGO & FORT WORTH, Texas–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. The lead development program is a unique Reactive …

Read More »